ArticleJournal of family medicine and primary care2022
Blood pressure-lowering effect of telmisartan compared to losartan among mild to moderate essential hypertensive adult subjects: A meta-analysis.
Article in Journal of family medicine and primary care, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 11 citations in OpenAlex.
- Review
- Comparative efficacy and safety of six angiotensin II receptor blockers in hypertensive patients: a network meta-analysis.International journal of clinical pharmacy · 2024Review
- Design of Experimental Approach for Development of Rapid High Performance Liquid Chromatographic Process for Simultaneous Estimation of Metoprolol, Telmisartan, and Amlodipine from Formulation: Greenness and Whiteness Evaluation.Molecules (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: We conducted a meta-analysis in which the blood pressure (BP)-reducing effect of telmisartan was compared to losartan among hypertensive subjects and its association with ethnicity, age, and gender was investigated. Materials and Methods: PubMed, Google Scholar, and the Cochrane library were searched from inception to April 2021 to obtain relevant articles. Cochrane risk of bias assessment tool was used for assessment of bias risk. GRADE analysis was done for determining the certainty of evidence. Data was analyzed using Revman 5.4.2 software. The pooled mean difference with 95% confidence interval (CI) was computed using random-effects model. Heterogeneity was also assessed using meta-regression and subgroup analysis. This study has been registered in PROSPERO with registration no. CRD42021245122. Results: Fifteen randomized controlled trials (RCTs) with 1926 subjects were selected from various countries. Both systolic BP (SBP) and diastolic BP (DBP) were found to be significantly reduced among telmisartan-treated groups (weighted mean difference [WMD] = 2.69, 95% CI: 1.38-4.00 and WMD = 1.26, 95% CI: 0.45-2.08 respectively). One subgroup analysis noted better reduction in both SBP and DBP among Asian population compared to Caucasians. Conclusion: Telmisartan was found to be a better hypertensive drug compared to losartan in patients with mild to moderate hypertension. Its efficacy was higher in Asian population compared to Caucasian population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.